After raising more than $268,828 ($360,000 Canadian dollars) since 2017 for Cystic Fibrosis Canada, thyssenkrupp Elevator Canada received the nonprofit’s 2019 National Champion Award. The award recognizes companies, service groups, and other entities that have a presence in at least three regions of Canada and have provided exceptional…
News
AzurRx BioPharma has launched a Phase 2b clinical trial investigating its MS1819 as a potential treatment for exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF). The first patient has now been screened in the OPTION 2 trial (NCT04375878), which has opened at three…
The Welsh government and Vertex Pharmaceuticals have reached an agreement that will allow access to the company’s Kaftrio (ivacaftor/tezacaftor/elexacaftor) for cystic fibrosis (CF) patients as soon as the medication is approved in Europe. Kaftrio is a triple combination therapy for the treatment of CF, designed to…
ContraFect has been awarded to $18.9 million by the nonprofit investment group CARB-X to advance CF-370 as a potential treatment for Pseudomonas aeruginosa infections. These bacteria and the thick layer of biofilm they produce are a major cause of pulmonary exacerbations in cystic fibrosis (CF) patients. CARB-X, which stands for…
Levels of inflammatory markers in the lungs may help predict pulmonary exacerbations in children with cystic fibrosis (CF), a new study suggests. The study, “BAL inflammatory markers can predict pulmonary exacerbations in children with cystic fibrosis,” was published in the journal Chest. In people…
Trikafta (elexacaftor/tezacaftor/ivacaftor combo) improves lung function in cystic fibrosis (CF) patients who have one F508del mutation and either one gating mutation (F/G) or one residual function mutation (F/RF) in the CFTR gene, new clinical trial data show. That finding was announced by Vertex Pharmaceuticals, which markets Trikafta.
Measuring levels of a molecule called lipoarabinomannan, or LAM, in a person’s urine could be an easier way of screening for airway infections due to nontuberculous mycobacteria in people with cystic fibrosis (CF), a study suggests. The study, “Urine lipoarabinomannan as a marker for low-risk…
Scientists have discovered that Vav3, a protein that is over-produced in the lining of the lungs of people with cystic fibrosis (CF), promotes lung infections by creating a “docking station” that bacteria such as Pseudomonas aeruginosa use to attach themselves to the lungs. Finding a way to inhibit…
A new technology could enable faster and more accurate cystic fibrosis (CF) diagnoses by non-invasively tracking the movement of air through even the fine structures of the lungs at high-resolution. A study done in mice showed this technology, called X-ray velocimetry (XV), could pinpoint localized areas of abnormal airflow…
Patient dosing has begun in a Phase 1b trial evaluating Calithera Bioscience’s oral therapy CB-280 for cystic fibrosis (CF) patients with chronic airway infections, the company announced. The study (NCT04279769), currently enrolling eligible adults at its two U.S. sites, will test four escalating…
Your CF Community
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.